TheracosBio Extends Collaboration with Mark Cuban Cost Plus Drug Company to Expand Access to BRENZAVVY

TheracosBio is delighted to announce the extension of its collaboration with the esteemed Mark Cuban Cost Plus Drug Company, furthering our joint mission to improve access to BRENZAVVY® (bexagliflozin). Building upon the successful launch of BRENZAVVY® in 2023, where it was made available directly to patients at transparent, affordable prices through the online pharmacy of Mark Cuban Cost Plus Drugs, we are excited to expand our reach.

Through this extended partnership, BRENZAVVY® will now be accessible to healthcare businesses via the innovative Cost Plus Drugs Marketplace program. This initiative aims to provide healthcare providers with convenient access to BRENZAVVY®, empowering them to better serve their patients managing diabetes. By offering the medication at cost-effective rates, we are committed to supporting frontline providers in their efforts to enhance patient care and address the challenges of diabetes management effectively.